What Was Behind Anacor's 28% Climb?
This episode of The Motley Fool's Market Checkup dives into the hottest headlines, looks at the biggest market movers in the health-care sector, and discusses the implementation of the Affordable Care Act.
This segment from the show focuses on Anacor's 28% surge after it announced that it will get $100 million from an arbitration ruling against drugmaker Valeant Pharmaceuticals . Analysts David Williamson and Max Macaluso discuss the impact of this ruling on both stocks in the following video.
Incredible growth stock to watch
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!
The article What Was Behind Anacor's 28% Climb? originally appeared on Fool.com.
Alison Southwick has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals International. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.